Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Paraganglioma 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Advanced Malignant Neoplasm 1Adenoma, Islet Cell 1

Interventions

Capecitabine 3Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Leucovorin 2Everolimus 2Bevacizumab 2vatalanib 1tipifarnib 1temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1aflibercept 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Salts 1Oxaliplatin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Somatostatinoma × Acetates × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡